These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

449 related items for PubMed ID: 20394211

  • 1. [More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD)].
    Adam Z, Nedbálková M, Krejcí M, Pour L, Husek K, Veselý K, Cermáková Z, Krivanová A, Mayer J, Hájek R.
    Vnitr Lek; 2010 Mar; 56(3):240-6. PubMed ID: 20394211
    [Abstract] [Full Text] [Related]

  • 2. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z, Krejcí M, Pour L, Stepánková S, Cermáková Z, Voska L, Teplan V, Krivanová A, Hájek R, Mayer J.
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [Abstract] [Full Text] [Related]

  • 3. [A patient with AL amyloidosis and severe factor X deficiency has been in complete haematological remission with normal factor X activity for 7 years following high-dose chemotherapy. A case study and literature review].
    Adam Z, Matýková M, Krejcí M, Pour L, Kissová J, Slechtová M, Chlupová G, Stavarová Y, Simonides J, Penka M, Mayer J, Hájek R.
    Vnitr Lek; 2010 Jan; 56(1):67-78. PubMed ID: 20184115
    [Abstract] [Full Text] [Related]

  • 4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
    Samanez C, Domingo A, Cibeira MT, Miquel R, Soler M, Bladé J.
    Eur J Haematol; 2006 Jan; 76(1):83-5. PubMed ID: 16343276
    [Abstract] [Full Text] [Related]

  • 7. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
    Sezer O, Schmid P, Shweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H, Possinger K.
    Bone Marrow Transplant; 1999 May; 23(9):967-9. PubMed ID: 10338056
    [Abstract] [Full Text] [Related]

  • 8. [Monoclonal gammopathy of undetermined significance and asymptomatic multiple myelom in the year 2014 ].
    Adam Z, Krejčí M, Pour L, Sevčíková E, Křivanová A, Rehák Z, Koukalová R, Cermáková Z, Vaníček J, Sevčíková S.
    Vnitr Lek; 2014 Oct; 60(10):861-79. PubMed ID: 25382009
    [Abstract] [Full Text] [Related]

  • 9. [Serum free light-chain assay for nonsecretory multiple myeloma with light chain cast nephropathy and light chain deposition disease].
    Honma R, Fukase S, Suzuki M, Omoto E.
    Rinsho Ketsueki; 2010 Apr; 51(4):270-4. PubMed ID: 20467224
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of refractory multiple myeloma with vincristine, adriamycin, dexamethasone, and with repeated application of cyclophosphamide (C-VAD).
    Adam Z, Elbl L, Vorlicek J, Hájek R, Hájek D, Hejlová N, Králová E, Novotná H.
    Acta Med Austriaca; 1994 Apr; 21(4):111-5. PubMed ID: 7871966
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
    Hernández-Reyes J, Galo-Hooker E, Ruiz-Delgado GJ, Ruiz-Argüelles GJ.
    Rev Invest Clin; 2012 Apr; 64(6 Pt 2):604-8. PubMed ID: 23593777
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
    Adam Z, Pour L, Krejcí M, Zahradová L, Krivanová A, Mardová J, Kovárová L, Stepánková S, Moulis M, Kren L, Veselý K, Svobodová I, Germáková Z, Nedbálková M, Mayer J, Hájek R.
    Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
    [Abstract] [Full Text] [Related]

  • 15. Incidence and evolution of monoclonal gammopathy of undetermined significance (MGUS) in Greece.
    Anagnostopoulos A, Evangelopoulou A, Sotou D, Gika D, Mitsibounas D, Dimopoulos MA.
    Ann Hematol; 2002 Jul; 81(7):357-61. PubMed ID: 12185503
    [Abstract] [Full Text] [Related]

  • 16. [A long-term observation of development from monoclonal gammopathy of undetermined significance (MGUS) into primary amyloidosis].
    Kanoh T, Yago K, Okuma M.
    Rinsho Ketsueki; 1990 Oct; 31(10):1740-4. PubMed ID: 2255066
    [Abstract] [Full Text] [Related]

  • 17. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
    Bridoux F, Delbes S, Sirac C, Pourreau F, Puyade M, Desport E, Jaccard A, Fermand JP, Touchard G.
    Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Renal involvement in benign monoclonal gammopathies: an underdiagnosed condition].
    Ramos R, Poveda R, Bernís C, Ara J, Sunyer M, Arrizabalaga P, Grinyó JM.
    Nefrologia; 2008 Mar; 28(5):525-9. PubMed ID: 18816211
    [Abstract] [Full Text] [Related]

  • 20. Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in Germany.
    Eisele L, Dürig J, Hüttmann A, Dührsen U, Assert R, Bokhof B, Erbel R, Mann K, Jöckel KH, Moebus S, Heinz Nixdorf Recall Study Investigative Group.
    Ann Hematol; 2012 Feb; 91(2):243-8. PubMed ID: 21789623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.